Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Guselkumab (/ɡjuˈsɛlkjumæb/ gew-SEL-kew-mab; sold under the brand name Tremfya) is a human monoclonal antibody against interleukin-23 used for the treatment of plaque psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease.
History, Community, Culture & Applications
Explore the main themes, entities and connections around Guselkumab. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
treatment approved psoriatic arthritis plaque psoriasis ulcerative colitis tremfya us gew-sel-kew-mab fda patients crohn's disease adalimumab ustekinumab human administration ɡjuˈsɛlkjumæb
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Guselkumab | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Guselkumab | ATC code | L04AC16 (WHO) | 1.00 | infobox |
| Guselkumab | CAS Number | 1350289-85-8 | 1.00 | infobox |
| Guselkumab | ChemSpider | none | 1.00 | infobox |
| Guselkumab | DrugBank | DB11834 | 1.00 | infobox |
| Guselkumab | Formula | C6402H9864N1676O1994S42 | 1.00 | infobox |
| Guselkumab | KEGG | D10438 | 1.00 | infobox |
| Guselkumab | Legal status | AU: S4 (Prescription only) | 1.00 | infobox |
| Guselkumab | Legal status | CA: Rx-only, Schedule D | 1.00 | infobox |
| Guselkumab | Legal status | UK: POM (Prescription only) | 1.00 | infobox |
| Guselkumab | Legal status | US: ℞-only | 1.00 | infobox |
| Guselkumab | Legal status | EU: Rx-only | 1.00 | infobox |
| Guselkumab | License data | US DailyMed: Guselkumab | 1.00 | infobox |
| Guselkumab | MedlinePlus | a617036 | 1.00 | infobox |
| Guselkumab | Molar mass | 143561.59 g·mol−1 | 1.00 | infobox |
| Guselkumab | Pregnancy category | AU: B1 | 1.00 | infobox |
| Guselkumab | Pronunciation | /ɡjuˈsɛlkjumæb/ gew-SEL-kew-mab | 1.00 | infobox |
| Guselkumab | Routes of administration | Subcutaneous, intravenous | 1.00 | infobox |
| Guselkumab | Source | Human | 1.00 | infobox |
| Guselkumab | Target | IL23 | 1.00 | infobox |
| Guselkumab | Trade names | Tremfya | 1.00 | infobox |
| Guselkumab | Type | Whole antibody | 1.00 | infobox |
| Guselkumab | UNII | 089658A12D | 1.00 | infobox |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.